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A B S T R A C T
Background
Acute lung injury , and acute respiratory distress syndrome , are syndromes of severe respiratory failure. Children with acute lung injury
or acute respiratory syndrome have high mortality and significant morbidity. Partial liquid ventilation is proposed as a less injurious
form of respiratory support for these children. Uncontrolled studies in adults have shown improvement in gas exchange and lung
compliance with partial liquid ventilation A single uncontrolled study in six children with acute respiratory syndrome showed some
improvement in gas exchange during three hours of partial liquid ventilation.
Objectives
To assess whether partial liquid ventilation reduces either mortality or morbidity, or both, in children with acute lung injury or acute
respiratory syndrome .
Search strategy
We searched The Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library issue 2, 2003; MEDLINE (1966
to April 2003); and CINAHL (1982 to April 2003); intensive care journals and conference proceedings; reference lists and ’grey
literature’.
Selection criteria
Randomized controlled trials which compared partial liquid ventilation with other forms of ventilation, in children (28 days - 18
years) with acute lung injury or acute respiratory syndrome, reporting one or more of the following: mortality; duration of mechanical
ventilation, respiratory support, oxygen therapy, stay in the intensive care unit, or stay in hospital; infection; or long term cognitive
impairment or neurodevelopmental progress or other long term morbidities.
Data collection and analysis
Two reviewers independently evaluated the quality of the relevant studies and extracted the data from the included studies.
Main results
Only one study enrolling 182 patients (only reported as an abstract in conference proceedings) was identified and found eligible
for inclusion: the authors report only limited results. The trial was stopped prematurely and therefore under-powered to detect any
significant differences. The only outcome of clinical significance available was 28 day mortality: there was no statistically significant
difference between groups with a relative risk for 28 day mortality in the partial liquid ventilation group of 1.54 (95% confidence
intervals of 0.82 to 2.9).
Authors’ conclusions
There is no evidence from randomized controlled trials to support or refute the use of partial liquid ventilation in children with acute
lung injury or acute respiratory syndrome: adequately powered, high quality randomized controlled trials are still needed to assess its
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efficacy. Clinically relevant outcome measures should be assessed (mortality at discharge and later, duration of respiratory support and
hospital stay, and long-term neurodevelopmental outcomes) and the studies should be published in full.
P L A I N L A N G U A G E S U M M A R Y
There is no evidence from randomized controlled trials (RCT) to support or refute the use of partial liquid ventilation in children with
severe lung disease.
Severely ill children can get severe lung disease that stops enough oxygen getting into the blood - this is called acute lung injury or
acute respiratory distress syndrome. About half of these children die. To improve the supply of oxygen to the body and prevent further
injury to the lung, a special liquid (perfluorocarbon liquid) is introduced into the lungs to partly replace the gas in normally gas-filled
lungs. This is called partial liquid ventilation (PLV). Only one poorly reported trial has been done on PLV in children and this does
not provide enough evidence to support its use.
B A C K G R O U N D
Acute lung injury (ALI), known in its most severe form as acute
respiratory distress syndrome (ARDS), is a syndrome of severe res-
piratory failure characterized by acute onset, severe hypoxaemia
and bilateral chest infiltrates on chest x-ray, without evidence of
left heart failure. ARDS was first described by Ashbaugh in 1967
(Ashbaugh 1967) in a case series that included one 11 year old
child. The causes of ALI or ARDS are many and they may re-
sult from primary lung disease (pneumonia, aspiration or inhala-
tion injury, lung trauma, fat emboli, near-drowning) or extra-
pulmonary causes (septicaemia, trauma and shock, cardio-pul-
monary bypass, drug overdose, acute pancreatitis, transfusion)
(Ware 2000). Malignancy and infection (septicaemia or pneumo-
nia) are common underlying antecedents in children (Timmons
1991; DeBruin 1992; Davis 1993).
ALI or ARDS results in poor matching of ventilation and perfusion
within the lung, and subsequent severe hypoxaemia. This situation
is known as ventilation-perfusion (V/Q) mismatch. They are also
characterized by severe heterogeneous atelectasis and decreased
lung compliance. Hence, patients with ALI or ARDS universally
require respiratory support and the mainstay of treatment is endo-
tracheal intubation and mechanical ventilation (Tobin 2001). The
syndromes are also characterized by a prominent pulmonary and
systemic inflammatory response. There is loss of integrity of the
alveolar-capillary barrier in the lung with increased inflammatory
cell and oxygen free radical mediated injury and increased pul-
monary and systemic pro-inflammatory cytokines (Ware 2000).
ALI or ARDS is further complicated by ventilator-induced lung
injury (VILI) and its secondary inflammatory effects. VILI arises
through either overdistention of the lung (volutrauma), the use of
high pressure within the lung (barotrauma), or a combination of
these factors. Decreasing baro- and volu-trauma may lower mor-
tality and morbidity (Tobin 2001; van der Werf 2001).
Generally accepted mortality figures for ALI or ARDS in adults
have ranged from 40 to 60% (Ware 2000); although recent stud-
ies have shown decreasing mortality over time in adults (Milberg
1995; Abel 1998). Mortality in children seems to be somewhat
greater with typical rates higher than 60% (Timmons 1991; De-
Bruin 1992; Davis 1993; Costil 1995; Paret 1998). Mortality is
often due to the primary disease process, especially septicaemia
or the associated multiple organ system failure (MOSF), rather
than respiratory failure per se (Pfenninger 1996; Monchi 1998;
Zilberberg 1998; Ware 2000) and therefore may not be amenable
to alterations in ventilatory techniques.
Recent studies show a lower mortality with ’protective’ ventilatory
strategies and/or an ’open-lung’ approach in adults with ARDS.
This suggests that VILI does have a role in increasing mortality;
and that decreasing baro- and volu-trauma may lead to improved
survival (Abel 1998; Amato 1998; ARDS Network 2000; Tobin
2001; Baudouin 2001; van der Werf 2001). A recent Cochrane
systematic review (Petrucci 2004) on ventilation with lower tidal
volumes versus traditional tidal volumes in adults with ALI or
ARDS concluded that whilst short-term mortality was reduced by
using ventilation with lower tidal volume there was insufficient
evidence to draw any conclusions about morbidity and long term
outcomes. Mortality and other outcomes have been shown to vary
by the sex and age of the patient, the initial severity of the ALI or
ARDS or patients condition and by the underlying cause of the
ALI or ARDS (DeBruin 1992; Davis 1993; Monchi 1998; Paret
1998; Ware 2000; Suntharalingam 2001).
There is also substantial short and long term morbidity associated
with these syndromes. Short term morbidity leads to prolonged
ventilator dependence and prolonged stay in the intensive care
unit (ICU) and hospital. Long term morbidity includes decreased
lung function, decreased health related quality of life, neuro-de-
velopmental delay, cognitive impairments, and high rates of dis-
ability (Fanconi 1985; Schelling 2000; Rothenhausler 2001).
The mainstay of treatment of ALI or ARDS is mechanical ven-
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tilation. Many forms of additional therapies have been consid-
ered and some of these subjected to randomized controlled trials.
Adjuncts to mechanical ventilation have included - extracorpo-
real life support (ECLS), inhaled nitric oxide, endogenous sur-
factant, prone positioning, high frequency ventilation and a va-
riety of pharmaceutical therapies (anti-inflammatory medication,
antioxidants, anticytokine agents, prostaglandins) (Sarnaik 1994;
Conner 2000). The ventilatory techniques that seem to improve
outcomes in ALI or ARDS are the ’lung-protective’ strategies that
aim to decrease VILI (Brower 2000; van der Werf 2001).
Partial liquid ventilation (PLV) has been proposed as a less inju-
rious form of respiratory support for patients with severe respira-
tory failure, ALI and ARDS. In 1991 Fuhrman et al (Fuhrman
1991) introduced the technique of using functional residual capac-
ity (FRC) volumes of perfluorocarbon liquid (PFC) with conven-
tional gas ventilation; they called it perfluorocarbon associated gas
exchange (PAGE). This technique has become known as PLV and
consists of partially filling the lungs with PFC whilst continuing
mechanical ventilation with a gas ventilator. Of the available tech-
niques of liquid assisted ventilation it is PLV which has the most
promise for practical clinical application in intensive care. Vari-
ous models of acute lung injury have shown the benefits of using
PLV compared with conventional mechanical ventilation alone.
Many animal studies have shown that PLV improves oxygenation,
CO2 removal and lung compliance, and leads to less lung damage
and VILI (Davies 1999; Wiedemann 2000). All of these benefits
are able to be achieved whilst using lower ventilatory pressures
and smaller tidal volumes (Davies 1999; Wiedemann 2000). PLV
also gives superior alveolar recruitment in the dependent areas of
the lung and redistributes pulmonary blood flow to improve V/Q
matching and decrease intra-pulmonary shunting (Davies 1999;
Wiedemann 2000). PFCs have also been demonstrated to have
significant anti-inflammatory effects in both in vivo animal mod-
els of ALI and in vitro cell cultures (Wiedemann 2000). PFCs
can decrease inflammatory cytokine release and oxygen free rad-
ical production by alveolar macrophages and decrease neutrophil
activation and chemotaxis (Wiedemann 2000).
Uncontrolled human studies using PLV in adults with ALI or
ARDS have shown improvement in oxygenation and lung com-
pliance in patients also on ECLS (Hirschl 1996), and improved
gas exchange with haemodynamic stability and minimal adverse
side effects in patients ventilated with PLV alone (Hirschl 1998).
The efficacy of PLV in adults with ALI or ARDS is the subject
of systematic review currently being prepared (Davies 2003). A
single uncontrolled study in six children with ARDS showed some
improvement in gas exchange with three hours of PLV (Fedora
1999a). The optimal dose of PFC to use during PLV is unknown
and its beneficial effects may be apparent at lower doses of PFC
than the usual method where the initial dose of PFC is equivalent
to the functional residual capacity (approx. 30 ml/kg). Variations
in the technique of PLV may also include giving an initial dose
of PFC with or without further top-up doses to maintain partial
filling of the lungs (Davies 1999).
O B J E C T I V E S
The primary objective was to assess whether PLV reduces reduces
either mortality or morbidity, or both, in children with ALI or
ARDS.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomized, controlled trials (RCTs). Cross-over studies were to
be excluded due to their inability to determine differences for
clinically relevant medium to long term outcomes.
Types of participants
Children from the age of 28 days to 18 years with ALI or ARDS
from any cause who are intubated and are being supported by a
mechanical ventilator.
Definition of ALI (Bernard 1994):
1. Acute onset respiratory failure
2. Bilateral opacities on chest x-ray consistent with pulmonary
oedema
3. Pulmonary artery wedge pressure less than 18mmHg or no
clinical evidence of raised left atrial pressure
4. PaO2 or FiO2 ratio less than or equal to 300mmHg.
Definition of ARDS (Bernard 1994):
1. Acute onset respiratory failure
2. Bilateral opacities on chest x-ray consistent with pulmonary
oedema
3. Pulmonary artery wedge pressure less than or equal to 18mmHg
or no clinical evidence of raised left atrial pressure
4. PaO2 or FiO2 ratio less than or equal to 200mmHg.
Types of intervention
Partial liquid ventilation (partially filling the lungs with PFC whilst
continuing mechanical ventilation with a gas ventilator) compared
with other forms of ventilatory management without the use of
perfluorocarbon liquids or vapour.
Types of outcome measures
One or more of the following outcomes must have been reported:
Mortality (28 day, or at discharge from ICU, at discharge from
hospital, or at 1, 2, and 5 years)
Duration of mechanical ventilation
Duration of respiratory support
Duration of oxygen therapy
Duration of stay in the intensive care unit
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Duration of stay in hospital
Infection (septicaemia, pneumonia)
Long term cognitive impairment
Long term neurodevelopment (cerebral palsy, sensorineural hear-
ing loss, visual impairment and/or developmental delay)
Long term disability
Long term health related quality of life
Long term lung function
Cost
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Anaesthesia Group methods used in reviews.
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL), The Cochrane Library issue 2, 2003; MEDLINE
(from 1966 to April 2003),CINAHL (from 1982 to April 2003),
intensive care journals and conference proceedings; reference lists
and ’grey literature’ for RCTs of PLV in ALI or ARDS.
The MeSH headings and text words applied (MEDLINE) were:
MeSH heading :’RESPIRATORY DISTRESS SYNDROME,
ADULT’ or textwords ’ARDS’, ’ALI’ or ’acute lung injury’ and
MeSH heading ’FLUOROCARBONS’ or textword ’partial liq-
uid ventilation’. The other databases were searched using a similar
strategy.
(Please note: that the MeSH term ’RESPIRATORY DISTRESS
SYNDROME, ADULT’ is the MeSH term for ALI or ARDS
whether it occurs in children or adults.)
• Bibliographies of published trials and conference proceedings,
were reviewed.
• We attempted to identify unpublished trials by contacting ex-
pert informants in the field of PLV research.
• No language restrictions were applied.
M E T H O D S O F T H E R E V I E W
The standard methods of the Cochrane Collaboration and its
Anaesthesia Review Group were used. The two reviewers worked
independently to search for and assess trials for inclusion and
methodological quality. Differences were resolved by discussion
and consensus of the reviewers.
Studies were assessed using the following key criteria: 1. allocation
concealment (blindness of randomization), 2. blindness of inter-
vention, 3. completeness of follow up, and 4. blinding of outcome
measurement. Each were rated as either adequate, unclear or in-
adequate. At least two criteria must have been rated as adequate
for the study to be included in the review.
Data were extracted independently by the reviewers. Differences
were resolved by discussion and consensus of the reviewers. If nec-
essary, investigators were to be contacted for additional informa-
tion or data.
For individual trials categorical outcomes, such as mortality, the
relative risk and risk difference (and 95% confidence intervals)
were reported.
Sub-group analyses were planned to determine whether the results
differ by:
Population:
i. age
ii. severity - of a. overall illness (e.g. APACHE or SAPS score), or
b. of ALI or ARDS
iii. aetiology of ALI or ARDS (e.g. septicaemia, pneumonia,
trauma, burns, etc)
Mortality and other outcomes have been shown to vary by the age
of the patient, the initial severity of the ALI or ARDS or patients
condition (e.g. by APACHE score) and by the underlying cause
of the ALI or ARDS (Monchi 1998; Ware 2000; Suntharalingam
2001).
Intervention:
i. initial amount or dose of PFC
ii. whether continuous PLV or intermittent doses of PFC
iii. type of PFC (e.g. perflubron, Rimar, etc)
The correct dose of PFC to use when initiating PLV is unknown.
Variations in the technique of PLV may also include giving an ini-
tial dose of PFC with or without further top-up doses to maintain
partial filling of the lungs. Various types of PFC with different
physical and chemical properties may be used. (Davies 1999).
Co-interventions:
i. use of inhaled nitric oxide
ii. use of surfactant
iii. use of the prone position
iv. high frequency ventilation
Whilst the mainstay of treatment of ALI or ARDS is mechanical
ventilation, additional therapies have been considered and some of
these subjected to randomized controlled trials. Adjuncts to me-
chanical ventilation have included inhaled nitric oxide, endoge-
nous surfactant, prone positioning, and high frequency ventila-
tion (Conner 2000): all can be used in conjunction with PLV.
D E S C R I P T I O N O F S T U D I E S
Eleven reports of nine studies were initially located by the search
strategy. Eight of the studies were excluded (see Table: Character-
istics of Excluded Studies). There were no disagreements between
reviewers.
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Only one study (Fuhrman 1998) was identified and found eligible
for inclusion in this review. It has only been reported as an abstract
in conference proceedings. We have contacted the first author
of this study and the company that sponsored it and no further
information or data are forthcoming from either source.
The study ran from January 1996 to April 1997 and enrolled 182
patients in 65 centres. At enrolment patients were allocated to re-
ceive either PLV (N=91) or conventional mechanical ventilation
(control group, N=91). The study was complicated by the fact that
entry criteria, use of other rescue therapies and the primary out-
come were modified at least twice during the study. These modifi-
cations included liberalization of the entry criteria and allowed use
of adjunct therapies in the control group, such as high frequency
ventilation and/or inhaled nitric oxide. The study was stopped
well short of expected recruitment (less than 20%) because of an
“abrupt decline” in mortality in the control group. Mortality at
28 days was 22% in the PLV group and 14% in the control group,
but this difference did not reach statistical significance. It is not
clear why the study did not continue thereafter. Other outcomes
reported for PLV versus control were: overall mortality (not de-
fined) 26% versus 20%; 28 day respiratory mortality 10% versus
10%; ventilator free days (not defined) 10.1 versus 12.4; and air
leak 33% versus 30%. None of these outcomes showed statistically
significant differences.
M E T H O D O L O G I C A L Q U A L I T Y
In Fuhrman et al’s study (Fuhrman 1998):
- treatment allocation was randomized (exact method not stated);
- whether allocation was adequately concealed is unknown;
- treatment was not blinded;
- follow-up rate not reported;
- whether the published outcomes were assessed by blinded eval-
uators is unknown (blinding of the assessment of death is not ap-
plicable).
The fact that entry criteria, use of other rescue therapies and the
primary outcome were modified at least twice during the study,
and that these are not adequately described in the abstract, makes
it difficult to assess the impact of the modifications on the quality
of the data available.
Also, each study centre enrolled an average of only 2.8 patients
into the study (182 patients in 65 centres) - many of these centres
would only have enrolled one or two patients into the study and
many would have only treated one child with PLV. This may have
led to wide variation in the application of PLV, the success of which
may well be determined in part by how the PLV is applied.
R E S U L T S
Limited results are available from only one study (Fuhrman 1998)
which was stopped prematurely. The only outcome of clinical
significance available from the only published report of this trial
was 28 day mortality; although not reported we assumed 100%
follow-up for analysis of this short-term outcome. There was no
statistically significant difference between groups for this outcome
with a relative risk for 28 day mortality in the PLV group of 1.54
(95% confidence intervals of 0.82 to 2.9).
D I S C U S S I O N
The study by Fuhrman et al (Fuhrman 1998) was stopped pre-
maturely and was therefore under-powered to detect any signifi-
cant differences. The wide 95% confidence intervals for 28 day
mortality mean that a clinically significant difference cannot be
excluded.
While it has been suggested that PLV is a promising alternative
mode of mechanical ventilation for children with ALI or ARDS,
there are no data from adequately powered RCTs available to de-
termine whether PLV is effective or not in decreasing morbidity
or mortality.
It is unfortunate that the only RCT investigating PLV in children
with ALI or ARDS done so far (Fuhrman 1998) has not been
published in full or that data on more clinically relevant outcomes
(especially mortality at discharge and later, duration of respira-
tory support and hospital stay, and long term neurodevelopmental
outcomes) is not forthcoming from the study investigators or the
company that sponsored the trial. The limited information avail-
able from the published abstract of this study makes it difficult to
make a complete assessment of study quality.
The under-reporting of RCTs due to publication bias has been
well described (Dickersin 1987; Dickersin 1990; Dickersin 1993).
In a systematic review of pharmaceutical industry sponsorship and
research outcome Lexchin et al (Lexchin 2003) found that research
funded by drug companies was less likely to be published. Some
consider the selection of reports for publication on the basis of
“positive results”, or the failure of investigators to publish results
with sufficient detail to allow judgments to be made about their
validity as scientific misconduct (Chalmers 1990). It is unknown
whether any of these factors are operating here.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence from RCTs to support or refute the use of
PLV in children with ALI or ARDS.
Implications for research
If children with ALI or ARDS are to be treated with PLV then
adequately powered, high quality RCTs are still needed to assess its
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efficacy. Clinically relevant outcome measures should be assessed
(especially mortality at discharge and later, duration of respiratory
support and hospital stay, and long term neurodevelopmental out-
comes) and the studies should be published in full.
P O T E N T I A L C O N F L I C T O F
I N T E R E S T
None known.
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